
Supplementary Materials

Neuromedin S Regulates Steroidogenesis through Maintaining Mitochondrial Morphology and Function via NMUR2 in Goat ovarian Granulosa Cells

Xuan Sun¹, Cheng Zeng^{1,2}, Feng Wang¹, Zhen Zhang¹, Fan Yang¹, Zhi-Peng Liu¹, Kang Li¹ and Guo-Min Zhang^{1,2,*}

¹ Jiangsu Livestock Embryo Engineering Laboratory, Nanjing Agricultural University, Nanjing 210095, China

² College of veterinary medicine, Nanjing Agricultural University, Nanjing 210095, China

* Correspondence: zhangguomin@njau.edu.cn; Tel.: +86-025-84395381

Table S1. The nucleotide of amplified sequence and NCBI reference sequence blast results.

Amplified sequence genes	NCBI reference sequence Accession	Max Score	Total Score	Query Cover	Per. Ident	Acc. Len
NMS	XM_005686290.2	907	907	98%	99.20%	708
NMUR1	XM_005676958.2	2370	2370	100%	98.94%	1800
NMUR2	XM_005683202.3	1816	1816	99%	99.50%	2150

Table S2. Details of primer sequences, expected product sizes and Genebank accession numbers of gene cloning.

Items	Primer sequence (5'-3')	Genebank No.	Fragment size (bp)
NMS	F: GGTTGTCTTGCCGGTGGAA R: ATTGCCTGATCCAGACTCGG	XM_005686290.2	577
NMUR1	F: GAGCGGATCCAGGAACCAAG R: TTGGGGTGAAGCAGCATGAG	XM_005676958.2	1383
NMUR2	F: GTCTTGCATTTAATAGCAGTTATGGA R: AGAGTACAGAACACACAGGGA	XM_005683202.3	1270

Table S3. Accession number of amino acid sequence.

Items	NMS Genebank No.	NMUR1 Genebank No.	NMUR2 Genebank No.
Goat	ACS32212.1	XP_005677015.2	XP_005683259.1
Cattle	NP_001070990.1	XP_002685694.3	NP_001030220.1
Pig	XP_020944053.1	NP_001302643.1	NP_001302544.1
Human	NP_001011717.1	AAH36543.1	NP_064552.3
Mouse	NP_001298717.1	AAI37776.1	AAI37612.1

Table S4. Details of siRNA sequences used for GCs transfection.

Gene	Sense (5'-3')	Antisense (5'-3')
NMUR1-goat-974	GGACACAGGUGACCAAGAUATT	AUCUUGGUACCCUGUGUCCTT
NMUR1-goat-774 (siNMUR1)	CCCGAGAGCCAUCUACAAATT	UUUGUAGAUGGCUCUCGGGTT
NMUR1-goat-1100	UCCAGUACGUGCACGUCAUTT	AUGACGUGCACGUACUGGATT
NMUR2-goat-650	GCAUCAAGCUCCACUACUUTT	AAGUAGUGGAGCUUGAUGCTT
NMUR2-goat-844 (siNMUR2)	GCAGAUAAAGUGACUGCAATT	UUGCAGUCACUUUAUCUGCTT
NMUR2-goat-844 (siNMUR2)	CCAGAAAGGAACUCUCAAATT	UUUGAGAGUUCCUUUCUGGTT
YAP1-goat-1817 (siYAP1)	CCGCCACCAAGCUAGAUATT	UUAUCUAGCUUGGUGGCCGGTT
Negative control	UUCUCCGAACCUGUCACGUTT	ACGUGACACGUUCGGAGAATT

Table S5. Details of primer sequences, expected product sizes and Genbank accession numbers of genes used for qPCR.

Items	Primer sequence (5'-3')	Genebank No.	Fragment size (bp)
NMS	F: ATTGTGAAGTTGAGCGGATGG R: CTGCCAGACCGATTAGAGGG	XM_005686290.2	205
NMUR1	F: GAGCGGATCCAGGAACCAAG R: AACAGAGAGGAACCTGAGCC	XM_005676958.2	210

	F: GTGTTGCTATCTGCTGGC		
NMUR2	R: GGTAGAAGAACACACCTGACACC	XM_005683202.3	320
	F: GGTCCCCGAGACTTGAG		
STAR	R: AATCCACTTGGGTCTGCGAG	XM_013975437.2	262
	F: CACTTCGCCACATCGAGAAC		
CYP11A1	R: AGGCTCCTGACTTCTAACAGG	NM_001287574.1	217
	F: AGACCAGAACAGTTGGGAGGAA		
3BHSD	R: TCTCCCTGTAGGAGTTGGGC	XM_013962473.2	292
	F: TGGTGTCCGAAGTTGCGCTATTG		
CYP19A1	R: AAGGTCGAACAGCTTCCAGAGTG	XM_013967046.2	393
MST1 (STK4)	F: TCAGATCAACAGCTTCGGCA		
	R: ACCGTCCAGCTTCAAGAAC	XM_013968939.2	105
MST2 (STK3)	F: CAGCGCCAAGAGTAAGCTA		
	R: GCCACAACTTGACCAGATTCC	XM_018058284.1	148
LATS1	F: CTCATCAGCAACGTCTACATCG		
	R: TCTTGAGATAATCCAACCCGCA	XM_018053335.1	70
LATS2	F: AGTGCTCCTCCGGAAAGGTTA		
	R: GCGTGCTCTCCCAGTTAAC	XM_018056548.1	146
YAP1	F: TGACCCTCGTTTGCCATGA		
	R: TCTGTTGCTGCTGGTTGGAA	XM_018059884.1	128
MFN1	F: ATCAGGGAGGTTACAGAGGAGGTTG	XM_018047540.1	226

	R: GGGATTGAAGCATTGAAGCGTTGAC		
	F: GTTGGTGGAGGAGTGGTGTGGAAG		
MFN2		XM_018060333.1	301
	R: TCTGGTTCATGGCGGCGATTTC3		
	F: GAACGCAGCATTGTTACAGACTTGG		
OPA1		XM_005675105.2	363
	R: AGCCTGTTGTTCAACTGACTCTCG		
	F: TTCCAATTATGCCAGCCAGTCCAC		
DNM1L		XM_018048322.1	294
	R: GTGCCATGTCCTCAGATTCACTCAG		
	F: CTGAACGAGTTGGTGTCTGTGGAG		
FIS1		XM_005697811.3	304
	R: GGTTGTTCTGCGGCTCTGTCTG		
	F: GGTGGAACAGACGGGTCG		
ClpP		XM_018050927.1	157
	R: GGGCTTCTTGTTGCTTCCG		
	F: CCAAGCAACCAAAGAACCCAGC		
PKR		XM_018055124.1	179
	R: CTTTGATGCCCTTCCAGT		
	F: ATGGGCTACAAAGAGAACGTTGATA		
JNK		XM_018051622.1	177
	R: ATTCCCTCACAGTTGGCTGAAGT		
	F: GGAAACGACCTCTACGACGATGC		
JUN		XM_018044742.1	243
	R: CCGTTGCTGGACTGTATGATGAGG		
	F: CGTTGCTGTGTTGAAGGTTGG		
HSP60		XM_018061271.1	153
	R: AAGGCTGGAATGCACCGAAG		
	F: CCGTTGACAGATAGCCGTAA		
GAPDH		XM_005680968.3	296
	R: CCGTTGACAGATAGCCGTAA		

Table S6. Details of antibodies.

Antibodies name	Cat NO.	Source	Dilutions used	Dilutions used	Dilutions used
			in IHC	in WB	in IF
NMS antibody	DF4237	LTD (USA)	1:250	1:800	1:200
Anti-NMUR1 antibody	AF9133	LTD (USA)	1:250	1:1000	1:200
NMUR2 polyclonal antibody	bs-11421R	Bioss (Beijing, China)	1:250	1:500	1:200
StAR polyclonal antibody	bs-3570R	Bioss (Beijing, China)	—	1:1000	—
CYP11A1 polyclonal antibody	bs-10099R	Bioss (Beijing, China)	—	1:1000	—
Anti-HSD3B1 antibody	NB110-78644SS	Novus (USA)	—	1:200	—
Cytochrome P450 19A1 antibody	DF6884	LTD (USA)	—	1:2000	—
STK4/MST1 polyclonal antibody	22245-1-AP	ProteinTech (IL, USA)	1:200	1:2000	1:100
STK3/MST2 polyclonal antibody	12097-1-AP	ProteinTech (IL, USA)	1:200	1:2000	1:200

Anti-MST1/2(Phospho-Thr183) antibody	D155304 (Shanghai, China)	BBI	-	1:500	-
LATS1 polyclonal antibody	17049-1-AP (IL, USA)	ProteinTech	1:200	1:2000	1:100
Anti-LATS2 antibody	D260914 (Shanghai, China)	Sangon Biotech	1:200	1:1000	1:100
Anti-LATS1/2(Phospho-Ser909/872) antibody	D155305 (Shanghai, China)	BBI	-	1:1000	-
YAP1 polyclonal antibody	13584-1-AP (IL, USA)	ProteinTech	1:200	1:2000	1:100
Anti-YAP1(Phospho-Ser127) antibody	D151452 (Shanghai, China)	BBI	-	1:1000	-
PGC1 alpha polyclonal antibody	NBP1-04676SS (USA)	Novus	-	1:500	-
Phospho-PGC1 α (S571) polyclonal antibody	AF6650-SP (USA)	R&D systems	-	1:1000	-
NFN1 polyclonal antibody	13798-1-AP (IL, USA)	ProteinTech	-	1:1000	-
NFN2 polyclonal antibody	12186-1-AP (IL, USA)	ProteinTech	-	1:4000	-
OPA1 polyclonal antibody	27733-1-AP (IL, USA)	ProteinTech	-	1:2000	-

		(IL, USA)		
DRP1(C-terminal) polyclonal antibody	12957-1-AP	ProteinTech (IL, USA)	-	1:2000
FIS1 polyclonal antibody	10956-1-AP	ProteinTech (IL, USA)	-	1:2000
CLPP polyclonal antibody	15698-1-AP	ProteinTech (IL, USA)	-	1:4000
Anti-EIF2AK2(PKR) antibody	bs-1493R	Bioss (Beijing, China)	-	1:500
JNK1/2/3 polyclonal antibody	51153-1-AP	ProteinTech (IL, USA)	-	1:1000
Phospho- JNK1/2/3(Thr183+Tyr185) polyclonal antibody	AF3318	LTD (USA)	-	1:500
Phospho-JUN(Ser73) polyclonal antibody	28891-1-AP	ProteinTech (IL, USA)	-	1:1000
HSP60 antibody	AF5374	LTD (USA)	-	1:1000
GAPDH Mouse Monoclonal antibody	60004-1-Ig	ProteinTech (IL, USA)	-	1:8000

HRP-conjugated				
Affinipure Goat Anti-	SA00001-2	ProteinTech	-	1:5000
Rabbit IgG(H+L)		(IL, USA)		-
HRP-conjugated				
Affinipure Goat Anti-	SA00001-1	ProteinTech	-	1:5000
Mouse IgG(H+L)		(IL, USA)		-
Goat Anti- Rabbit IgG		Abcam		
H&L (DyLight® 650)	ab96886		1:100	-
		(IL, USA)		-

IHC: immunohistochemistry, WB: Western blot, IF: immunocytochemistry, (-): absent.

Figure S1. Analysis of goat NMS and its receptor amino-acid sequences. Multiple alignments of deduced amino-acid sequences of NMS and its receptor in several species. The lack of 19 amino acids of the goat NMS was shown in the red box, and the core structure of NMS binding with its receptors show in the black box. Transmembrane region of the goat NMUR1and NMUR2 amino-acid sequence fragment. 101-123aa, 135-157aa, 177-199aa, 219-241aa, 270-292aa, 335 - 357aa and 372-394aa, NMUR1 transmembrane sequence; 48-70aa, 82-104aa, 124-146aa, 167-189aa, 216-238aa, 270 - 292aa and 307-329aa, NMUR2 transmembrane sequence. Identifiers: “**” identical, “.” and “:” conservative replacements, “” mismatches.




Figure S2. NMS receptors interference efficiency verification in goat granulosa cells. (A) The mRNA expression of NMUR1 in goat GCs under siNMUR1-774, siNMUR1-974, and siNMUR1-1100 treatment was determined by qPCR. (B) The protein expression of NMUR1 in goat CSs under siNMUR1-774, siNMUR1-974, and siNMUR1-1100 treatment was shown by western blot. (C) The mRNA expression of NMUR2 in goat GCs under siNMUR2-650, siNMUR2-844, and siNMUR2-1301 treatment was determined by qPCR. (D) The protein expression of NMUR2 in goat GCs under siNMUR2-650, siNMUR2-844, and siNMUR2-1301 treatment was shown by western blot. The data are expressed as fold change. Data are presented as mean \pm S.E.M. of the results obtained in at least three independent experiments. Different letters indicate significant differences in the expressions between the groups ($P < 0.05$).




Figure S3. YAP1 interference and overexpression efficiency verification in goat granulosa cells. (A) The mRNA expression of YAP1 in goat GCs under siYAP1-1817 treatment was determined by qPCR. (B) The protein expression of YAP1 in goat GCs under siYAP1-1817 treatment was determined by western blot. (C) The mRNA expression of oeYAP1 treatment in goat GCs was determined by qPCR. (D) The protein expression of oeYAP1 treatment in goat GCs was determined by western blot. Data are presented as mean \pm S.E.M. value from at least three individuals. Different letters indicate significant differences in the expressions between the groups ($P < 0.05$).